Cat. No. 5309
Chemical Name: N-[3,5-Bis(trifluoromethyl)phenyl]-
Biological ActivityPotent dual inhibitor of NF-κB and AP-1 transcriptional activity (IC50 = 50 nM). Blocks production of IL-2, IL-8 and TNF-α from Jurkat T cells. Inhibits cytokine production selectively in T cells; exhibits minimal inhibition of cytokine production in other cell types. Decreases arthritic severity in a mouse model of collagen-induced arthritis. Also ameliorates muscle wasting in a rat model of cancer cachexia.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Moore-Carrasco et al (2007) The AP-1/NF-κB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. Int.J.Oncol. 30 1239. PMID: 17390027.
Gerlag et al (2000) The effect of a T cell-specific NF-κB inhibitor on in vitro cytokine production and collagen-induced arthritis J.Immunol. 165 1652. PMID: 10903776.
Sullivan et al (1998) 2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3',5'- bis(trifluoromethyl)phenyl)-carboxamide: a potent inhibitor of NF-κB- and AP-1-mediated gene expression identified using solution-phase combinatorial chemistry. J.Med.Chem. 41 413. PMID: 9484492.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses SP 100030 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: SP 100030, supplier, SP100030, potent, dual, inhibitors, inhibits, nf-kb, nf-kappab, nf-κb, blocks, cytokine, production, selective, t, cells, immunosuppressive, anti-inflammatory, Tocris Bioscience, NF-κB and IκB Inhibitor products
Find multiple products by catalog number
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.